Two years cancer-free: Imugene’s breakthrough VAXINIA therapy
Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has reported a significant achievement in its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial. The company announced that a patient with bile tract cancer has now maintained a complete response (remission) for over two years. This highlights the potential of Imugene’s therapy, VAXINIA, which utilises an engineered virus […]
Two years cancer-free: Imugene’s breakthrough VAXINIA therapy Read More »